LON:COG Cambridge Cognition (COG) Share Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free COG Stock Alerts GBX 56.20 +1.20 (+2.18%) (As of 03/28/2024 04:35 PM ET) Add Compare Share Share Today's Range 53.25▼ 56.2050-Day Range 48▼ 57.8952-Week Range 47.23▼ 106Volume21,502 shsAverage Volume69,827 shsMarket Capitalization£19.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Cambridge Cognition alerts: Email Address Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cambridge Cognition Stock (LON:COG)Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.Read More COG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COG Stock News HeadlinesMarch 29, 2024 | msn.comIt's Tricky to Know Which Supplements Are Safe — Here's What to AvoidMarch 28, 2024 | msn.comCanadian rower looking forward to third outing for Oxford in historic Boat RaceMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | msn.comChronic alcohol use is linked to impaired plasticity of brain inhibition networks, study suggestsMarch 22, 2024 | americanbankingnews.comCambridge Cognition (LON:COG) Stock Crosses Below 200-Day Moving Average of $60.69March 21, 2024 | msn.comMemory-Boosting Supplements Could Lack Compounds and Contain BacteriaMarch 17, 2024 | msn.comI’ll do it later: my quest to stop procrastinatingMarch 17, 2024 | mirror.co.uk'Our brains compensate for decline as we grow older by recruiting other areas'March 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 15, 2024 | msn.comSome people are genetically predisposed to gain weight. These 5 tips can helpMarch 13, 2024 | theguardian.comMPs must act to save young drivers’ livesMarch 11, 2024 | msn.comBiden classified-documents-case special counsel set to testify Tuesday in HouseFebruary 24, 2024 | msn.comStudy: Dietary supplements fail versus prescription drugs with same active ingredientFebruary 24, 2024 | msn.comMemory supplements lack ingredients touted for Alzheimer's patients, study findsFebruary 19, 2024 | dailymail.co.ukI'm a dementia expert who spent 25 years caring for patients… now I've been diagnosed with Alzheimer's myself. This is what I'm doing to slow down the diseaseFebruary 19, 2024 | msn.comWould You Live in a City That Forced You to Exercise?February 15, 2024 | msn.comBrains compensate for age-related deterioration by recruiting other areas, Cambridge and Sussex scientists showFebruary 8, 2024 | msn.comBrain adapts to compensate for age-related decline, study showsFebruary 7, 2024 | msn.comNeuroscience research uncovers key brain region that helps offset age-related cognitive declineFebruary 6, 2024 | msn.comThe SAT is a pathway to more college diversity, not lessFebruary 6, 2024 | nytimes.comHow to Hunt the SasquatchFebruary 5, 2024 | nytimes.comIt’s ‘Liquid Gold’ for Newborns. But Can It Help Your Health?February 5, 2024 | msn.comEveryone used to hate cubicles. Now we long to have them back.February 2, 2024 | msn.comPlaying an Instrument or Singing May Help You Keep Your Mind SharpFebruary 1, 2024 | msn.com1 in 10 cases of dementia may be misdiagnosed liver cirrhosis, study findsJanuary 31, 2024 | msn.comBiogen pulls controversial Alzheimer's drug AduhelmJanuary 30, 2024 | lse.co.ukTRADING UPDATES: Synthomer predicts revenue decline amid challengesSee More Headlines Receive COG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambridge Cognition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/22/2020Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:COG CUSIPN/A CIKN/A Webwww.cambridgecognition.com Phone44 1223 810 700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.11) Trailing P/E RatioN/A Forward P/E Ratio41.04 P/E GrowthN/ANet Income£-3,740,000.00 Net Margins-29.25% Pretax MarginN/A Return on Equity-630.55% Return on Assets-13.31% Debt Debt-to-Equity Ratio18.95 Current Ratio0.45 Quick Ratio0.96 Sales & Book Value Annual Sales£12.77 million Price / Sales1.54 Cash FlowGBX 13.05 per share Price / Cash Flow4.31 Book ValueGBX 3 per share Price / Book18.73Miscellaneous Outstanding Shares34,960,000Free FloatN/AMarket Cap£19.65 million OptionableNot Optionable Beta0.76 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Matthew William Stork (Age 56)CEO & Director Comp: $342kMr. Stephen Daniel Symonds (Age 49)CFO & Executive Director Comp: $203.31kMr. John HammondCo-FounderMr. Nick TaptiklisHead of Technology StrategyMs. Francesca Cormack Ph.D.Chief ScientistMr. Simon MerrittMarketing and Communications DirectorDr. Lisa Elizabeth Nolan Ph.D. (Age 62)Vice President Business Development Ms. Nicky AckerleyGlobal HR DirectorProf. Trevor RobbinsSenior ConsultantProf. Barbara Sahakian FMedSciFBPsS, Senior ConsultantMore ExecutivesKey CompetitorsFeedbackLON:FDBKInduction Healthcare GroupLON:INHCRenalytixLON:RENXOxford BioDynamicsLON:OBDOptiBiotix HealthLON:OPTIView All Competitors COG Stock Analysis - Frequently Asked Questions How have COG shares performed in 2024? Cambridge Cognition's stock was trading at GBX 51.50 at the beginning of the year. Since then, COG shares have increased by 9.1% and is now trading at GBX 56.20. View the best growth stocks for 2024 here. How were Cambridge Cognition's earnings last quarter? Cambridge Cognition Holdings Plc (LON:COG) announced its quarterly earnings results on Tuesday, September, 22nd. The company reported ($1.50) EPS for the quarter. Cambridge Cognition had a negative trailing twelve-month return on equity of 630.55% and a negative net margin of 29.25%. What other stocks do shareholders of Cambridge Cognition own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambridge Cognition investors own include Interserve (IRV), Alio Gold Inc. (ALO.TO) (ALO), Concepta PLC (CPT.L) (CPT), European Metals (EMH), IntelGenx Technologies (IGXT), Oxford Biomedica (OXB), Syneos Health (SYNH), Travelers Companies (TRV), Amryt Pharma (AMYT) and AltynGold (ALTN). How do I buy shares of Cambridge Cognition? Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:COG) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambridge Cognition Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.